Introduction
============

Disbudding, the removal of calves\' horn buds, is a common procedure in dairy animal husbandry, but the procedure causes severe acute pain, and is associated with behavioural and physiological responses ([@b18]; [@b16]; [@b22]). There is no EU legislation for pain management associated with disbudding. [@b5] allows any skilled person to destroy or remove the horn-producing area of calves aged \<4 weeks by chemical or heat cauterization.

Application of appropriate anaesthetics and analgesics is not compulsory in most countries but it is strongly recommended ([@b2]; [@b19]; [@b3]). Cornual nerve block and ring block around the horn buds with local anaesthetics effectively alleviates disbudding pain or delays its onset ([@b10]; [@b7]). However infiltration of local anaesthetics to non-sedated calves is often difficult. Disbudding-related postoperative pain has been successfully alleviated by non-steroidal anti-inflammatory drugs, such as meloxicam ([@b23]; [@b11]), ketoprofen ([@b16]; [@b6]) and carprofen ([@b24]).

Despite recommendations, pain and distress related to disbudding of calves often remains untreated ([@b12]; [@b25]; [@b9]). According to the [@b1], it is assumed that some kind of medical treatment is administered prior to or after calf disbudding only on 20% of European farms. In Italy, producers reported that 10% of their disbudded calves received local anaesthetics, 4% received a sedative and 5% received analgesics prior to disbudding ([@b9]). In Canada, use of sedatives or local anaesthetics was reported for 45% of herds, but no analgesics (NSAIDs) were mentioned ([@b25]). In the United States, sedatives or local anaesthetics were utilized by 12% and analgesics by 2% of dairy farmers ([@b8]).

Detomidine is a potent α~2~-adrenoceptor agonist that is used commonly for sedation or premedication in horses and cattle, including calves ([@b20]). Sublingual administration of an oromucosal gel formulation of detomidine produced safe sedation in horses (DiMaio [@b4]; [@b13]), and the bioavailability was approximately 22% ([@b13]).

The primary objective of this study was to explore the use of oromucosal detomidine gel for sedation of calves prior to disbudding. Our hypothesis was that oromucosal detomidine would produce sufficient sedation to allow administration of local anaesthetics with minimum resistance. The secondary objective was to determine the plasma detomidine concentrations after sublingual administration and to compare level of sedation to intravenous (IV) administration of detomidine in calves undergoing disbudding.

Materials and methods
=====================

This study was conducted with permissions of the Animal Experiment Board of Finland and the Finnish Medicines Agency. Twenty clinically healthy dairy calves of both sexes were included. Their age was 12.4 ± 4.4 days (mean ± SD) and they weighed 50.5 ± 9.0 kg. The animals were disbudded as a routine measure of the farm. The calves were housed as other calves on the farm, and they were used to human handling. The calves were allocated randomly to one of two groups of 10 animals in each. One group was given sublingually (GEL) detomidine gel (Domosedan Gel 7.6 mg mL^−1^ oromucosal gel; Orion Pharma Ltd., Finland) 80 μg kg^−1^, the other group was given IV detomidine (Domosedan 10 mg mL^−1^ solution for injection; Orion Pharma Ltd.) 30 μg kg^−1^.

Prior to drug administration, the calves were examined clinically and the *V. cephalica* was cannulated (16 G Intraflon, 1.6 × 60 mm; Vygon, France) for blood sampling. In the IV group, the *V. jugularis* was also cannulated with a similar catheter for drug administration. Before placement of the catheters, local anaesthesia was provided by the subcutaneous infiltration of lidocaine (Lidocain 20 mg mL^−1^; Orion Pharma Ltd.).

The detomidine gel for sublingual administration was drawn into a 1 mL syringe to achieve an accurate dose, and was administered under the tongue of the calf. The IV detomidine was given as a bolus *via* the jugular catheter, which thereafter was flushed with 10 mL of isotonic saline. To alleviate postoperative pain, meloxicam (0.5 mg kg^−1^; Melovem 5 mg mL^−1^; Orion Pharma Ltd.) was administered subcutaneously. When clinical sedation was evident, the local anaesthetic, Lidocaine 20 mg mL^−1^, was injected subcutaneously around the cornual nerve and a ring block was inserted around both horn buds as previously described by [@b6]. The total dose of lidocaine was 3 mg kg^−1^ *per* calf. The animal\'s response to administration of the local anaesthetic was recorded. The adequacies of the local blocks were tested with needle pricks, and once adequate, hot cauterization was used to destroy the horn buds.

Heart rate (HR) was measured by auscultation and the depth of sedation was recorded using a 17-point (0--16 where 0 is no sedation) behaviour-based clinical sedation score (CSS) which was modified from [@b14]. Details are presented as supporting information (Appendix S1). The CSS was recorded at 14 time points for 240 minutes after drug administration.

Rectal temperature was measured with a digital thermometer prior to treatment and every 30 minutes thereafter. The pen of the calf had a soft insulated floor with a mattress and adequate sawdust. Calves were covered with blankets to maintain the body temperature. The ambient temperature in the pens was 10.0--19.4 °C during the study.

Venous blood samples (3 mL) were collected from the catheter in the *V. cephalica* into EDTA tubes for analysis of plasma detomidine concentrations. Times of collection were, for the IV group at 5, 10, 20, 30, 60, 120, 180, 240 minutes, and for the GEL group at 30, 60, 90, 120, 150, 180, 210, 240 minutes after drug administration. After each sampling the catheter was flushed with 5 mL of isotonic saline with heparin (10 IU mL^−1^). Samples were stored at room temperature prior to centrifugation. Plasma was separated by centrifugation (3000 ***g*** for 15 minutes) within three hours after sampling, frozen and stored at −20 °C until analysis.

Quantitative analysis of detomidine concentrations in plasma was performed with reversed phase liquid chromatography (Shimadzu Prominence HPLC instrument; Shimadzu Corporation, Japan) combined with mass spectrometric detection (AB Sciex API4000 triple quadrupole mass spectrometer, Framingham, MA, USA) using an internal standard method. Details are presented in the supporting information, Appendix S2.

Pharmacokinetic variables were calculated from the plasma detomidine concentration-time data with the WinNonlin Professional software package, version 5.3 (Pharsight Corporation, CA, USA) using non-compartmental methods. The areas under the time plasma concentration curve (AUC) and time sedation score curve (AUC~sed~) were calculated with the trapezoidal method. Bioavailability of detomidine after sublingual administration was approximated by using the formula 100% \* AUC~SL(avg)~/AUC~IV(avg)~ \* D~IV~/D~SL~, where D was the dose of detomidine. The AUCs and the maximum sedation scores detected for each animal were compared between administration routes using Student\'s *t*-test. The differences between administration routes in CSS and HR were compared with linear mixed models taking repeated samplings into account. Fixed factors were the sampling time, administration route and interaction between them. A calf was used as a random factor. Statistical analyses were performed using PASW 18.0.1 (SPSS Inc., IL, USA). *p* \< 0.05 was considered statistically significant.

Results
=======

Plasma detomidine concentrations are shown in Fig.[1](#fig01){ref-type="fig"}. The maximum plasma detomidine concentration (C~max~) after sublingual administration was 2.1 ± 1.2 ng mL^−1^ (mean ± SD), the time of maximum concentration (T~max~) was 66.0 ± 36.9 minutes, and the approximated bioavailability of detomidine was 34%. Pharmacokinetic parameters are shown in Table[1](#tbl1){ref-type="table"}.

###### 

Pharmacokinetic parameters and sedation scores (scale 0--16 where 0 = no sedation) after sublingual (80 μg kg^−1^) or intravenous (30 μg kg^−1^) of detomidine administration

                           Detomidine 80 μg kg^−1^ sublingually   Detomidine 30 μg kg^−1^ intravenously   *p*-value
  ------------------------ -------------------------------------- --------------------------------------- -----------
  C~max~ (ng mL^−1^)       2.1 ± 1.2                              --                                      --
  T~max~ (minutes)         66.0 ± 36.9                            --                                      --
  AUC~last~                226 ± 110                              252 ± 127                               0.62
  Maximum sedation score   9.9 ± 2.1                              10.7 ± 2.1                              0.40
  AUC~sed~                 1026 ± 477                             784 ± 209                               0.16

All values mean ± SD. *N *=* *10 animals per group.

![Mean ± SD plasma detomidine concentrations after sublingual (80 μg kg^−1^, solid line) and intravenous (30 μg kg^−1^, broken line) administration of detomidine to calves. *N *=* *10 per group.](vaa0041-0372-f1){#fig01}

The maximum sedation scores for each animal and the overall levels of sedation (AUC~sed~) did not differ between the treatments (Table[1](#tbl1){ref-type="table"}). Briefly, for the first 30 minutes after administration, CSS was higher in the IV than in the GEL group. Thereafter, CSS was higher in the GEL than in the IV group up to 210 minutes post administration (Fig.[2](#fig02){ref-type="fig"}). Heart rate decreased to a significantly lower level in the IV than in the GEL group (Fig.[3](#fig03){ref-type="fig"}).

![Mean ± SD composite sedation scores (0--16 where 0 is no sedation) after sublingual (80 μg kg^−1^, solid line) and intravenous (30 μg kg^−1^, broken line) administration of detomidine to calves. *N *=* *10 per group. \*Statistically significant difference (*p* \< 0.05) between the groups.](vaa0041-0372-f2){#fig02}

![Heart rate (mean ± SD) after sublingual (80 μg kg^−1^, solid line) and intravenous (30 μg kg^−1^, broken line) administration of detomidine to calves. *N *=* *10 per group. \*Statistically significant difference (*p* \< 0.05) between the groups.](vaa0041-0372-f3){#fig03}

Time from sedation to local anaesthetic administration was 11 minutes (range 5--20 minutes) in IV group and 38 minutes (range 25--55 minutes) in GEL group. None of the calves substantially resisted infiltration of the local anaesthetic nor reacted to hot cauterization of horn buds. All recoveries were eventless, and no adverse reactions were noted in any of the animals. All calves were able to stand up and walk at the end of the observation period. Rectal temperatures did not differ between the treatments, and hypothermia was not detected.

Discussion
==========

Our results indicated that sublingual administration of detomidine gel prior to infiltration of local anaesthetics was an effective method to sedate healthy calves for disbudding.

Venous blood from the oral mucosal membrane drains *via* the jugular veins into the systemic circulation, and thus during the absorption phase of the drugs administered by this route, blood from jugular vein may have substantially higher drug concentrations than the mixed blood in systemic circulation ([@b17]). Therefore plasma drug concentrations analyzed from the jugular vein following sublingual administration may not reflect systemic concentrations. We avoided this bias by collecting blood samples from the veins of extremities (*V. cephalica*).

In a previous study ([@b21]), the pharmacokinetic profile of parenterally administered detomidine in milking cows was close to that of adult horses. In our study, the approximated bioavailability of sublingually administered detomidine in calves (34%) seemed to be relatively similar to the previously reported bioavailability in horses (22%) ([@b13]). Our study was not designed to be a pharmacokinetic study, as our primary aim was to evaluate clinical sedation. We collected plasma samples up to 4 hours after drug administration, which probably affected the approximated bioavailability. The elimination phase (ß-phase) was not attained within the follow up time after sublingual administration, and thus we could not extrapolate the plasma concentration *versus* time curve to infinity.

As there was a risk that a fraction of the gel dose could be swallowed, we carefully administered the gel under the tongue. The volume of the gel was small (\<1 mL *per* calf) and it seemed to remain easily in the oral cavity. Detomidine might undergo extensive first-pass metabolism if swallowed, but the amount of this metabolism is not known in calves. Thus further studies are still needed about the pharmacokinetics of detomidine in calves with this administration route.

In general, the detomidine induced sedation was equal in both treatment groups. However, maximum sedation was reached earlier in the IV group than in the GEL group. This suggested that 80 μg kg^−1^ of detomidine administered sublingually was equally potent as 30 μg kg^−1^ of IV administered detomidine. The decrease in heart rate was less intense with sublingual administration than with parenteral administration, as reported earlier also for horses ([@b15]; [@b13]). Our findings imply that sublingual administration of detomidine would alleviate the decreases in heart rate observed with parenteral administration of detomidine. The efficacy and safety of detomidine after sublingual administration to calves needs further studies in various clinical indications.

In our study we measured regularly the rectal temperature of the animals. If needed, we used blankets to prevent hypothermia. Thus, hypothermia was not detected. It is important to monitor the body temperature and prevent its reduction in sedated animals as hypothermia affects drug metabolism and prolongs recovery.

We concluded that oromucosal detomidine gel is an effective sedative for calves prior to infiltration of local anaesthetics and to disbudding. This non-invasive and user-friendly oromucosal sedation method for calves could ease the use of local anaesthetics.
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Components of the composite sedation scores (0--16 points), modified from [@b14].
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Measurement of detomidine concentrations.
